Students using Archer Review continue to pass at 99+% compared to dropping NCLEX pass rates across the rest of the market The NCSBN has released the NCLEX pass rates for Q1 of 2025 (January - March).

The FDA has started a priority review of AstraZeneca and Amgen's severe asthma antibody tezepelumab, setting a date for a decision in the first quarter of 2022. If approved, TSLP inhibitor ...

After years of declining pass rates among U.S.-educated, first-time test takers, state nursing boards revised the NCLEX in 2023. The updated exam was designed to more precisely measure nurses ...

Roshni Naik, MD, allergist at Mount Sinai Health System, discusses treatment options for a case of severe asthma with nasal polyps: "Patient history of severe asthma and chronic sinusitis with polyps.

Given the excellent attendance at our initial pilot clinic (described above) review between 1 and 2 weeks following the index attack was considered as the optimal time. Ensuring Immediate Safe ...

What Is Exercise-Induced Asthma? It's when your airways squeeze or get narrow during physical activity. Its medical term is exercise-induced bronchoconstriction. It can cause coughing, wheezing ...

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations. BTS, NICE and SIGN have developed an asthma pathway, which brings together ...

Therefore, this umbrella review aims to objectively evaluate the quality of these SR/MAs and reassess the efficacy of biologic therapy for severe asthma. Methods: A systematic search was performed in ...

Several versions of action plans have been published but the key components have not been determined. A study was undertaken to determine the impact of individual components of written action plans on ...

Once you have chosen a healthcare provider for your asthma, transfer your medical records from any previous providers or medical facilities so your new practitioner can review your information. When ...

SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo ANCHOR-1 and -2 trials ...